Welcome to our dedicated page for Immutep American Depositary Shares news (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep American Depositary Shares stock.
Immutep Limited (NASDAQ: IMMP) is a globally active biotechnology company focusing on the development of innovative immunotherapy products for cancer and autoimmune diseases. Listed on both the Australian Stock Exchange and the Nasdaq Global Market in the U.S., Immutep is at the forefront of personalized bio-therapeutic treatment options.
At the core of Immutep's research and development is the LAG-3 immune control mechanism, crucial for the regulation of the T cell immune response. The company's flagship product, IMP321, a T cell immunostimulatory factor (APC activator), has completed Phase II clinical trials for cancer chemo-immunotherapy. This product is designed to enhance the body's immune response to cancer, providing a novel treatment option for patients.
In addition to IMP321, Immutep is advancing several other LAG-3 related products. These include IMP701, a blocking anti-LAG-3 antibody for cancer currently in Phase I clinical trials, and CVac, a personalized immunocellular therapeutic being investigated for the treatment of epithelial cancer. The development of these products is supported through partnerships with large pharmaceutical companies, aiming to accelerate the availability of these innovative treatments.
Immutep's operations are headquartered in Australia, with the majority of its revenue derived from product sales. The company remains committed to maximizing shareholder value through its technological expertise and robust pipeline of products.
For investors, Immutep represents a significant opportunity in the biotechnology sector, with its cutting-edge research and promising clinical advancements poised to make a substantial impact on cancer and autoimmune disease treatment.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced the successful completion of patient recruitment for the Phase II TACTI-002 study, targeting non-small cell lung cancer (NSCLC) and head & neck squamous cell carcinoma (HNSCC). With 185 patients enrolled across all study parts, recruitment was completed under 12 months, surpassing expectations. Interim data from Part C was presented at the SITC Annual Meeting 2021, with further results anticipated in early 2022. This milestone reflects Immutep's commitment to advancing immunotherapy research in challenging pandemic conditions.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced the grant of a new patent from the Chinese Patent Office for its immunotherapy candidate, eftilagimod alpha (efti or IMP321). The patent protects combined therapeutic preparations involving efti and anti-PD-1 or anti-PD-L1 antibodies, expiring on January 8, 2036. This follows similar patents granted in Europe and the U.S. between 2018 and 2021. The patent is exclusively licensed to EOC Pharma, which will pay milestone payments and royalties as efti progresses through trials in China.
Immutep Limited (NASDAQ: IMMP) presented promising data at the SITC Annual Meeting 2021, highlighting significant Overall Survival (OS) improvements in patient subgroups from its AIPAC trial. Key findings indicate a median OS of 22.3 months for patients under 65 and 32.5 months for those with low monocyte counts. The Phase II TACTI-002 study revealed a 29.7% Overall Response Rate (ORR) in second-line head and neck cancer patients. The company’s candidate, efti, continues to show potential for improving quality of life and long-term outcomes in cancer treatment.
Immutep Limited has reported promising results from the TACTI-002 trial, noting an Objective Response Rate (ORR) of 29.7% in patients with second-line head and neck squamous cell carcinoma (HNSCC). This study included 37 patients, with 5 achieving complete responses. Additionally, Immutep will recruit 154 first-line HNSCC patients for the TACTI-003 study to assess ORR as the primary endpoint. Detailed data from the AIPAC trial will be presented in an investor webcast on November 17, 2021.
Immutep Limited announced promising final overall survival (OS) data from its Phase IIb AIPAC trial, indicating a median OS of 20.4 months for patients treated with efti and paclitaxel, compared to 17.5 months with placebo. The trial demonstrated significant survival benefits in predefined patient subgroups: +7.5 months for patients <65 years, +19.6 months for those with low monocytes, and +4.2 months for luminal B cancers. A Phase III trial is planned, focusing on these results, which underline the efficacy of efti as an immunotherapy in metastatic breast cancer.
Immutep Limited (NASDAQ: IMMP) announced the grant of a new patent in China for its lead product candidate, eftilagimod alpha (efti). This patent, numbered ZL 201610221687, protects the use of efti combined with chemotherapy for cancer treatment, expiring on October 3, 2028. This addition to Immutep's patent portfolio follows similar grants in Europe, Japan, and the US. The patent is exclusively licensed to EOC Pharma, which will pay milestone fees and royalties as efti progresses in clinical development.
Immutep Limited (NASDAQ: IMMP) has received positive feedback from the European Medicines Agency (EMA) regarding its clinical development program for eftilagimod alpha (efti), particularly the planned Phase III trial in metastatic breast cancer (MBC). This follows encouraging results from the ongoing Phase IIb AIPAC trial. The EMA's support allows Immutep to proceed with the trial design, which will involve multiple countries. Additional regulatory discussions are ongoing with the US FDA.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced key developments in its clinical trials and financial situation for the quarter ended 30 September 2021. The company received approvals for the Phase IIb TACTI-003 trial and successfully enrolled the first patient in the INSIGHT-003 study. Preparations for a new Phase III trial (AIPAC-003) in metastatic breast cancer are ongoing. Financially, Immutep reported cash receipts of $56k and a cash balance of $106.39 million, enhancing its financial position with cash reach extending to December 2023.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced that data from its Phase II TACTI-002 trial will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021, held in Washington, US, from November 10-14, 2021. Additionally, results from the Phase IIb AIPAC trial will be shared as a late breaker poster presentation. The poster abstracts will be published on November 9, 2021, followed by new data on November 12, 2021. TACTI-002 evaluates efti with pembrolizumab in treating head and neck cancer patients.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced a significant cash boost of €2,126,617 (~ A$3,430,952) from the French Government via its Crédit d’Impôt Recherche scheme. This R&D tax incentive benefits the company’s European research efforts conducted during the 2020 calendar year. Additionally, Immutep received a A$1,155,055 rebate from the Australian Federal Government for similar activities. The funds will aid in the global clinical development of eftilagimod alpha and the preclinical development of IMP761.
FAQ
What is the current stock price of Immutep American Depositary Shares (IMMP)?
What is the market cap of Immutep American Depositary Shares (IMMP)?
What is Immutep Limited?
What products does Immutep specialize in?
What is the LAG-3 immune control mechanism?
What is IMP321?
What are the other key products in Immutep's pipeline?
With which markets is Immutep affiliated?
Where is Immutep headquartered?
What are Immutep's key partnerships?
How does Immutep generate revenue?
Why should investors consider Immutep?
